US2005069538A1PendingUtilityA1

Therapeutic binding molecules

56
Priority: Sep 18, 2003Filed: Sep 18, 2003Published: Mar 31, 2005
Est. expirySep 18, 2023(expired)· nominal 20-yr term from priority
Inventors:Gregorio AversaFrank KolbingerJose M. Carballido HerreraAndras AszodiJose SaldanhaBruce M. Hall
C07K 2317/74A61P 37/02A61P 37/00C07K 2317/24C07K 16/289C07K 2317/73A61K 2039/505C07K 2317/41C07K 2317/565C07K 2317/75C07K 2317/56C07K 2317/92
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1′, CDR2′ and CDR3′, CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gin (RASQNIGTSIQ), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.

Claims

exact text as granted — not AI-modified
1 . A binding molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT).  
     
     
         2 . A binding molecule according to  claim 1  comprising 
 a) a first domain comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); and    b) a second domain comprising in sequence the hypervariable regions CDR1′, CDR2′ and CDR3′, said CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT).    
     
     
         3 . A binding molecule according to  claim 1 , which is a chimeric or humanised monoclonal antibody.  
     
     
         4 . A binding molecule according to  claim 1 , comprising a polypeptide of SEQ ID NO:1 and/or a polypeptide of SEQ ID NO:2.  
     
     
         5 . A binding molecule according to  claim 1 , comprising a polypeptide of SEQ ID NO:3 and/or a polypeptide of SEQ ID NO:4.  
     
     
         6 . A binding molecule according to  claim 4  which is a chimeric monoclonal antibody.  
     
     
         7 . A binding molecule which is a humanised antibody comprising a polypeptide of SEQ ID NO:9 or of SEQ ID NO:10 and a polypeptide of SEQ ID NO:7 or of SEQ ID NO:8.  
     
     
         8 . A binding molecule which is a humanised antibody comprising 
 a polypeptide of SEQ ID NO:9 and a polypeptide of SEQ ID NO:7,    a polypeptide of SEQ ID NO:9 and a polypeptide of SEQ ID NO:8,    a polypeptide of SEQ ID NO:10 and a polypeptide of SEQ ID NO:7, or    a polypeptide of SEQ ID NO:10 and a polypeptide of SEQ ID NO:8.    
     
     
         9 . Isolated polynucleotides comprising polynucleotides encoding a binding molecule according to  claim 1 .  
     
     
         10 . Polynucleotides according to  claim 9  encoding the amino acid sequence of CDR1, CDR2 and CDR3, according to said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT).  
     
     
         11 . Polynucleotides comprising a polynucleotide of SEQ ID NO: 5 and/or a polynucleotide of SEQ ID NO: 6.  
     
     
         12 . Polynucletides comprising polynucleotides encoding a polypeptide of SEQ ID NO:7 or SEQ ID NO:8 and a polypeptide of SEQ ID NO:9 or SEQ ID NO:10.  
     
     
         13 . Polynucleotides comprising a polynucleotide of SEQ ID NO:1 1 or of SEQ ID NO:12 and a polynucleotide of SEQ ID NO:13 or a polynucleotide of SEQ ID NO:14.  
     
     
         14 . An expression vector comprising polynucleotides according to  claim 9 .  
     
     
         15 . An expression system comprising a polynucleotide according to  claim 9 , wherein said expression system or part thereof is capable of producing a binding molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT), when said expression system or part thereof is present in a compatible host cell.  
     
     
         16 . An isolated host cell which comprises an expression system according to  claim 15 .  
     
     
         17 . Use of a molecule or of a humanised antibody according to  claim 1  as a pharmaceutical.  
     
     
         18 . Use according to  claim 17  in the treatment and/or prophylaxis of autoimmune diseases, transplant rejection, psoriasis, inflammatory bowel disease and allergies.  
     
     
         19 . A pharmaceutical composition comprising a molecule or a humanised antibody according to  claim 1  in association with at least one pharmaceutically acceptable carrier or diluent.  
     
     
         20 . A method of treatment and/or prophylaxis of diseases associated with autoimmune diseases, transplant rejection, psoriasis, inflammatory bowel disease and allergies comprising administering to a subject in need of such treatment and/or prophylaxis an effective amount of a molecule or a humanised antibody according to  claim 1 .  
     
     
         21 . Use of a binding molecule having a binding specificity for both CD45RO and CD45RB in medicine.  
     
     
         22 . The use according to  claim 21 , wherein the binding molecule is a chimeric, a humanised or a fully human monoclonal antibody.  
     
     
         23 . The use according to  claim 21 , wherein the binding molecule binds to a CD45RO isoform with a dissociation constant (Kd) <15 nM.  
     
     
         24 . The use according to  claim 21 , wherein the binding molecule binds to a CD45RB isoform with a dissociation constant (Kd) <15 nM.  
     
     
         25 . The use according to  claim 21 , wherein the binding molecule binds CD45 isoforms which 
 include the A and B epitopes, but not the C epitope of the CD45 molecule; and/or    include the B epitope, but not the A and not the C epitope of the CD45 molecule; and/or    isoforms which do not include any one of the A, B or C epitopes of the CD45 molecule.    
     
     
         26 . The use according to  claim 21 , wherein the binding molecule does not bind CD45 isoforms which 
 include all of the A, B and C epitopes of the CD45 molecule; and/or    include both the B and C epitopes, but not the A epitope of the CD45 molecule.    
     
     
         27 . The use according to  claim 21 , wherein the binding molecule binds to its target epitope on PEER cells, and wherein said binding is with a Kd<15 nM.  
     
     
         28 . Polynucleotides encoding the amino acid sequence of CDR1′, CDR2′ and CDR3′, according to said CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3′ having the amino acid sequence Gln-GIn-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT).  
     
     
         29 . An expression system comprising a polynucleotide according to  claim 10 , wherein said expression system or part thereof is capable of producing a binding molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT), when said expression system or part thereof is present in a compatible host cell.  
     
     
         30 . An expression system comprising a polynucleotide according to  claim 11 , wherein said expression system or part thereof is capable of producing a binding molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT), when said expression system or part thereof is present in a compatible host cell.  
     
     
         31 . An expression system comprising a polynucleotide according to  claim 12 , wherein said expression system or part thereof is capable of producing a binding molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT), when said expression system or part thereof is present in a compatible host cell.  
     
     
         32 . An expression system comprising a polynucleotide according to  claim 13 , wherein said expression system or part thereof is capable of producing a binding molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT), when said expression system or part thereof is present in a compatible host cell.  
     
     
         33 . An expression system comprising a polynucleotide according to  claim 28 , wherein said expression system or part thereof is capable of producing a binding molecule of comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT), when said expression system or part thereof is present in a compatible host cell.

Join the waitlist — get patent alerts

Track US2005069538A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.